Our study not only reaffirms the beneficial role of the RIPK3 axis in initiating tumor immunity but also innovates it by presenting a dual-function necroptotic switch that mitigates the safety risks and elevates the immunotherapeutic potential of cancer cell–based therapies, providing a compelling case for clinical exploration. Here, RIPK3 is linked to neoplasm.